|
Recommendations for Vaccination Both TIV and LAIV prepared for the 2007-08 season will include A/Solomon Islands/3/2006 (H1N1)-like, A/Wisconsin/ 67/2005 (H3N2)-like, and B/Malaysia/2506/2004-like antigens. These viruses will be used because they are representative of influenza viruses that are anticipated to circulate in the United States during the 2007-08 influenza season and have favorable growth properties in eggs. TIV and LAIV can be used to reduce the risk for influenza virus infection and its complications. Immunization providers should administer influenza vaccine to any person who wishes to reduce the likelihood of becoming ill with influenza or transmitting influenza to others should they become infected. Healthy, nonpregnant persons aged 5-49 years can choose to receive either vaccine. TIV is FDA-approved for persons aged >6 months, including those with high-risk conditions, whereas LAIV is FDA-approved for use only among healthy persons aged 5-49 years (note). All children aged >6 months-8 years who have not been vaccinated previously at any time with either LAIV or TIV should receive 2 doses of age-appropriate vaccine in the same season, with a single dose during subsequent seasons. |